Post-earnings recap
Reported
Thu, Jul 29, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CRISPR Therapeutics reported a strong earnings surprise on EPS, indicating better-than-expected profitability. However, the stock reacted negatively, declining by 0.6%. The lack of revenue data and no forward guidance may have contributed to investor caution.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $9.44 | N/A | +125.57% |
| Revenue | N/A | N/A | N/A |
Management expressed confidence in the ongoing development of their therapies. However, they did not provide any updates on future guidance.
Management did not provide specific guidance for future quarters.
The company remains focused on advancing its pipeline of therapies.